Qiagen N.V. $QGEN Shares Acquired by Voya Investment Management LLC

Voya Investment Management LLC raised its stake in shares of Qiagen N.V. (NYSE:QGEN) by 52.3% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 245,657 shares of the company’s stock after purchasing an additional 84,332 shares during the quarter. Voya Investment Management LLC owned about 0.11% of Qiagen worth $9,845,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of QGEN. Price T Rowe Associates Inc. MD increased its stake in Qiagen by 3,030.9% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 4,470,728 shares of the company’s stock valued at $179,501,000 after purchasing an additional 4,327,934 shares in the last quarter. Wellington Management Group LLP increased its stake in Qiagen by 12.2% during the 1st quarter. Wellington Management Group LLP now owns 24,438,441 shares of the company’s stock valued at $972,191,000 after purchasing an additional 2,656,136 shares in the last quarter. Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in Qiagen during the 4th quarter valued at approximately $95,746,000. Deutsche Bank AG increased its stake in shares of Qiagen by 57.5% in the first quarter. Deutsche Bank AG now owns 4,491,131 shares of the company’s stock worth $180,319,000 after acquiring an additional 1,639,621 shares during the period. Finally, Nuveen LLC purchased a new position in shares of Qiagen during the first quarter worth $44,078,000. Institutional investors and hedge funds own 70.00% of the company’s stock.

Analyst Upgrades and Downgrades

QGEN has been the subject of several recent research reports. UBS Group raised their target price on shares of Qiagen from $48.00 to $50.00 and gave the stock a “neutral” rating in a report on Thursday, August 7th. Bank of America raised their target price on shares of Qiagen from $50.00 to $53.00 and gave the stock a “buy” rating in a report on Thursday, June 26th. Barclays initiated coverage on shares of Qiagen in a report on Tuesday, June 24th. They set an “overweight” rating and a $55.00 target price for the company. Cowen reissued a “hold” rating on shares of Qiagen in a report on Thursday, August 7th. Finally, Wall Street Zen cut shares of Qiagen from a “strong-buy” rating to a “buy” rating in a report on Monday, August 11th. Three equities research analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $49.69.

Qiagen Stock Up 0.5%

QGEN stock opened at $45.60 on Wednesday. The firm has a market cap of $10.14 billion, a PE ratio of 26.94, a P/E/G ratio of 2.40 and a beta of 0.64. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.35 and a current ratio of 1.61. The firm’s fifty day moving average is $48.38 and its 200 day moving average is $44.73. Qiagen N.V. has a one year low of $37.63 and a one year high of $51.88.

Qiagen (NYSE:QGEN) last released its quarterly earnings results on Tuesday, August 5th. The company reported $0.60 EPS for the quarter, meeting the consensus estimate of $0.60. The company had revenue of $533.54 million for the quarter, compared to analyst estimates of $523.97 million. Qiagen had a net margin of 18.30% and a return on equity of 14.77%. The firm’s revenue was up 7.7% on a year-over-year basis. During the same quarter last year, the business earned $0.55 earnings per share. Qiagen has set its Q3 2025 guidance at 0.580- EPS. FY 2025 guidance at 2.350-2.350 EPS. On average, research analysts forecast that Qiagen N.V. will post 2.26 EPS for the current year.

About Qiagen

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.